摘要
定量磁共振成像提供了重要的信息,在正常老化和退行性疾病的组织在大脑中的组织性能。虽然它是众所周知的,相较于对照组,阿尔茨海默氏症(AD)显示一个特定的模式和更快的速度,定量磁共振成像在阿尔茨海默氏症中的精确的空间和时间模式是未知的。我们的目的是调查的神经影像学相关的阿尔茨海默氏症使用序列定量磁共振成像。在我们的研究中,有阿尔茨海默氏症二十一名受试者和三十二名年龄相仿的健康对照者在基线和12个月时接受了2系列磁共振成像扫描。组织特征是使用两个磁共振成像定量参数捕获:纵向弛豫时间(qT1)和横向弛豫时间(qT2)。两组(阿尔茨海默氏症组和对照组)进行统计学使用基于体素的定量比较(VBQ)基于数字图像处理和数据处理教程方法。在基线时,与对照组在双侧颞叶和顶叶、海马、基底节区相比,阿尔茨海默氏症受试者纵向弛豫时间和横向弛豫时间表现出与显著降低。这种模式在后续也观察到了。纵向上,在阿尔茨海默氏症患者的双侧海马、丘脑和尾状核中,我们发现纵向弛豫时间和横向弛豫时间是一个显著的增加而不是时间从基线纵向进一步减少。此外,一般疾病的严重程度显著预测超过12个月的阿尔茨海默氏症双侧海马纵向弛豫时间增加,左侧海马的纵向弛豫时间纵向变化在一年期间,阿尔茨海默氏症的认知能力下降呈负相关。横向弛豫时间在左侧海马旁回与随时间变化的神经精神功能的纵向变化相关。总之,定量磁共振成像参数减少阿尔茨海默氏症截面,但随时间的增加而增加,表现出明显的时空模式的阿尔茨海默氏症萎缩,我们也证明了定量磁共振成像参数的临床相关性,表明其作为新标志物的潜在意义。
关键词: 阿尔茨海默病,淀粉样蛋白,早期诊断,弛豫时间,单体核磁共振,基于体素的量化。
Current Alzheimer Research
Title:Cortical and Subcortical Changes in Alzheimer’s Disease: A Longitudinal and Quantitative MRI Study
Volume: 13 Issue: 5
Author(s): Li Su, Andrew M. Blamire, Rosie Watson, Jiabao He, Benjamin Aribisala and John T. O’Brien
Affiliation:
关键词: 阿尔茨海默病,淀粉样蛋白,早期诊断,弛豫时间,单体核磁共振,基于体素的量化。
摘要: Quantitative MRI provides important information about tissue properties in brain both in normal ageing and in degenerative disorders. Although it is well known that those with Alzheimer’s disease (AD) show a specific pattern and faster rate of atrophy than controls, the precise spatial and temporal patterns of quantitative MRI in AD are unknown. We aimed to investigate neuroimaging correlates of AD using serial quantitative MRI. In our study, twenty-one subjects with AD and thirty-two similar-aged healthy controls underwent two serial MRI scans at baseline and 12 months. Tissue characteristics were captured using two quantitative MRI parameters: longitudinal relaxation time (qT1) and transverse relaxation time (qT2). The two groups (AD and controls) were statistically compared using a voxel based quantification (VBQ) method based on Matlab and SPM8. At baseline, subjects with AD showed a significant reduction of qT1 and qT2 compared to controls in bilateral temporal and parietal lobes, hippocampus, and basal ganglia. This pattern was also observed at follow-up. Longitudinally, in AD we found a significant increase rather than further reduction of qT1 and qT2 from the baseline in bilateral hippocampus, thalamus and right caudate nucleus. In addition, the longitudinal change of qT1 in left hippocampus was negatively correlated with cognitive decline in AD over the 1-year period, and the general disease severity significantly predicted the amount of increase of qT1 in bilateral hippocampus over 12 months. The longitudinal change of qT2 in left parahippocampus correlated with change in neuropsychiatric features over time. In summary, quantitative MRI parameters were reduced in AD cross-sectionally, but increased over time, showing distinct spatiotemporal patterns from the atrophy in AD. We also showed the clinical relevance of quantitative MRI parameters, indicating their potential promise as new imaging markers in AD.
Export Options
About this article
Cite this article as:
Li Su, Andrew M. Blamire, Rosie Watson, Jiabao He, Benjamin Aribisala and John T. O’Brien , Cortical and Subcortical Changes in Alzheimer’s Disease: A Longitudinal and Quantitative MRI Study, Current Alzheimer Research 2016; 13 (5) . https://dx.doi.org/10.2174/1567205013666151116141416
DOI https://dx.doi.org/10.2174/1567205013666151116141416 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 Receptors and their Role in the Modulation of Pain Response in the Central Nervous System
Current Neuropharmacology Antiepileptics and the Treatment of Neuropathic Pain: Evidence from Animal Models
Current Pharmaceutical Design Cholecystokinin Antagonists A New Way to Improve the Analgesia from Old Analgesics?
Current Pharmaceutical Design Clonidine: Clinical Pharmacology and Therapeutic Use in Pain Management
Current Clinical Pharmacology Extracellular Matrix Scaffolds for Tissue Engineering and Regenerative Medicine
Current Stem Cell Research & Therapy Pain-Related Behavior and Brain Activation in a Cynomolgus Macaque Model of Postoperative Pain
CNS & Neurological Disorders - Drug Targets Discovery of Nesfatin-1 and Overview of Biological Actions and New Developments
Current Pharmaceutical Design A Pivotal Role of the Nrf2 Signaling Pathway in Spinal Cord Injury: A Prospective Therapeutics Study
CNS & Neurological Disorders - Drug Targets Directed Differentiation and Paracrine Mechanisms of Mesenchymal Stem Cells: Potential Implications for Tendon Repair and Regeneration
Current Stem Cell Research & Therapy Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Current Medicinal Chemistry Synaptic and Extrasynaptic Glutamate Signaling in Ischemic Stroke
Current Medicinal Chemistry The Application of Stable Isotope Assisted Metabolomics in Biomedicine
Current Biotechnology TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Transcranial Magnetic Stimulation of Degenerating Brain: A Comparison of Normal Aging, Alzheimer’s, Parkinson’s and Huntington's Disease
Current Alzheimer Research Chest Pain in Children
Current Pediatric Reviews Pharmacological Targeting of the Epidermal Barrier
Current Pharmaceutical Design Neuropeptide Conversion to Bioactive Fragments - An Important Pathway in Neuromodulation
Current Protein & Peptide Science Stem Cell Therapy for Spinal Cord Injury
Current Medicinal Chemistry Opioids and Cannabinoids Interactions: Involvement in Pain Management
Current Drug Targets Nucleic Acids Delivery Systems: A Challenge for Pharmaceutical Technologists
Current Drug Metabolism